Replies to post #4433 on Dendreon Corp fka DNDNQ

[walldiver]

I would tend to disagree...the negatives in the briefing docs focused primarily on the missed primary endpoint of the main trial, be it 0.085 or 0.052. I was very surprised by the extent to which the FDA de-emphasized 9902A. The agency seemed to agree with DNDN's position that 9902A was an incomplete trial.